Welcome to the 
(Resource) Library


Several resources are available to help you prescribe and access LIVMARLI for your patients. Patient-friendly resources and videos are also available to share and discuss with your patients.

Mirum Access Plus Resources

Mirum Access Plus is available to help your patients not only get started with LIVMARLI after you’ve prescribed it, but also to provide support throughout treatment.

Mirum Access Plus Support Program

For new patients, you can begin treatment discussions by providing the Patient Brochure for an overview of LIVMARLI.

Visit the access section of the website to learn about the details of Mirum Access Plus support.

Mirum Access Plus Downloadable Resources

Resources are available through Mirum Access Plus to help you, your office, and your patients with everything from treatment costs to prescription fulfillment.

Additional LIVMARLI Resources

Resources for You

Itch Severity Tool

Learn how you can use clinically validated tools to rate itch severity over time.

Download PDF

Alagille Syndrome Flashcard

Reference this quick-hitting guide to get to know LIVMARLI at a glance.

Download PDF

Resources for Patients and Caregivers

Patient Website

Share this website with your patients to explain LIVMARLI treatment in a patient-friendly manner.

Visit Patient Website

Patient Brochure

Provide this resource to your patients considering or receiving LIVMARLI treatment.

Download PDF  

Discussion Guide

A short, simple list of questions to help your patients discuss LIVMARLI with you and gain more knowledge about and confidence in getting started.

Download PDF  

Teddy Activity Book

An educational children's book about Alagille syndrome that can help patients understand the disease through storytelling and engaging activities.

Download PDF

Cholestatic Pruritus Finder

A guide to help patients and caregivers recognize the signs and symptoms of cholestatic pruritus at any age.

Download PDF

Itch✓™ App

Itch✓ is an app that makes it simple for patients and caregivers to track symptom patterns over time. The app generates customized reports to share at appointments. 

Download on the Apple App Store®  |
Get it on Google Play

Itch✓ Printable Journal

Patients and caregivers without a smartphone can still bring a detailed symptom journal to their next appointment with the Itch✓ Printable Journal.

Download PDF  |  Español

Root Out
Excess Bile

Learn how LIVMARLI—the first FDA-approved treatment for cholestatic pruritus in Alagille syndrome—battles bile acid buildup.1

See How LIVMARLI Works

Encourage patients to download the Itch✓ app to help them track symptom patterns over time and generate customized reports to share at appointments.

Check Out the Itch✓ App

Mirum Access Plus assists both you and your patients at every turn, helping you navigate the payer approval process—and beyond—with ease.

Learn More About
Mirum Access Plus
Collapse icon

Important Safety Information


LIVMARLI is contraindicated in patients with prior or active hepatic decompensation events (eg, variceal hemorrhage, ascites, or hepatic encephalopathy).

Warnings and Precautions

Hepatotoxicity: LIVMARLI treatment is associated with a potential for drug-induced liver injury. In the Alagille syndrome trial, treatment-emergent elevations of liver tests or worsening of liver tests occurred.

Obtain baseline liver tests and monitor during treatment. Liver-related adverse reactions and physical signs of hepatic decompensation should also be monitored. Dose reduction or treatment interruption may be considered if abnormalities occur in the absence of other causes. For persistent or recurrent liver test abnormalities, consider treatment discontinuation. Permanently discontinue LIVMARLI if a patient experiences the following: persistent or recurrent liver test abnormalities, clinical hepatitis upon rechallenge, or a hepatic decompensation event.

Gastrointestinal (GI) Adverse Reactions: Diarrhea and abdominal pain were reported as the most common adverse reactions. Monitor for dehydration and treat promptly. Consider reducing the dosage or interrupting dosing if a patient experiences persistent diarrhea or has diarrhea with bloody stool, vomiting, dehydration requiring treatment, or fever.

Fat-Soluble Vitamin Deficiency: Patients can have fat-soluble vitamin (FSV) deficiency (vitamins A, D, E, and K) at baseline, and LIVMARLI may adversely affect absorption of FSV. If bone fractures or bleeding occur, consider interrupting LIVMARLI and supplement with FSVs. LIVMARLI can be restarted once FSV deficiency is corrected and maintained at corrected levels.

Adverse Reactions

The most common adverse reactions are diarrhea, abdominal pain, vomiting, FSV deficiency, liver test abnormalities, and bone fractures.

Drug Interactions

Administer bile acid binding resins at least 4 hours before or 4 hours after administration of LIVMARLI. A decrease in the absorption of OATP2B1 substrates (eg, statins) due to OATP2B1 inhibition by LIVMARLI in the GI tract cannot be ruled out. Consider monitoring the drug effects of OATP2B1 substrates as needed.

Dosing Information

LIVMARLI should be taken 30 minutes before a meal. The provided oral dosing dispenser must be used to accurately measure the dose. Any remaining LIVMARLI should be discarded 100 days after first opening the bottle.